14 results about "Cartilage degradation" patented technology

The invention relates to a diatomic iron-iron site nano-enzyme constructed by relieving oxidative stress and cartilage degeneration and used for targeted osteoarthritis treatment. According to the invention, a nitrogen-doped porous carbon anchored diatomic iron nano enzyme catalyst (Fe2-NCs) with Fe-Fe dimer coordination is developed by using a'subject-object 'strategy. The Fe2-NCs protect cartilage cells from oxidative stress induced apoptosis by modulating ROS and active nitrogen species (RNS) and promoting O2 release. In addition, Fe2-NCs restores mitochondrial function by inhibiting NOX4 expression, improving ATP production, and normalizing COXIV levels. In an in-vivo OA model, the Fe2-NCs can reduce the expression of a pro-inflammatory medium COX-2 through an NF-kappa B signal channel, inhibit the up-regulation of MMP-13 and delay the degradation of type II collagen. The invention provides a new theoretical framework and methodological approach for the treatment of osteoarthritis, and has important clinical and scientific significance.

Provided herein are methods of treating erosive hand osteoarthritis (OA) in a subject in need thereof, methods of reducing radiographic erosive progression, joint space narrowing, cartilage degradation, and / or bone formation in a subject in need thereof (e.g., a subject suffering from erosive hand OA), methods of inhibiting the development of new erosive joints in a subject in need thereof (e.g., a subject suffering from erosive hand OA), and methods of reducing pain in a subject with erosive hand OA. Also provided herein are uses of denosumab in the manufacture of a medicament adapted for use in a method described herein, as well as pharmaceutical compositions comprising denosumab for use in a method described herein.

Disclosed are compounds of Formula (I) useful as inhibitors of ADAMTS-5 and / or ADAMTS-4, pharmaceutical compositions thereof, and their use as therapeutic agents for the treatment of diseases involving cartilage degradation or destruction of cartilage homeostasis, in particular osteoarthritis and / or rheumatoid arthritis.

Compositions comprising a condensed mesenchymal cell body and a hydrogel are provided. The compositions may further include drugs or growth factors. The condensed mesenchymal cell body may include a connective tissue cell, or even a progenitor cell capable of producing connective tissue extracellular matrices such collagen and glycosaminoglycan. Also provided are methods of treating connective tissue defects, cartilage injury, and cartilage degradation.

This invention discloses the application of PT-129 in the preparation of drugs for treating rheumatoid arthritis (RA), belonging to the field of RA treatment. This invention is the first to demonstrate that the compound PT-129 can target and intervene in the synovial microenvironment, effectively inhibiting the abnormal activation behaviors of RA fibroblast-like synovial cells (FLS) such as proliferation, migration, and invasion, and downregulating the expression of N-cadherin and MMP3 proteins in synovial tissue. This invention provides a combined drug formulation containing PT-129 and RGFP966. This composition exhibits a significant synergistic effect in vivo, effectively relieving joint swelling, increasing bone density and trabecular bone thickness, reducing trabecular bone separation, thereby inhibiting cartilage degradation and bone destruction. This invention provides a novel targeted drug and combination therapy with definite efficacy for the clinical intervention of RA, possessing extremely high clinical application development value.

The invention provides a composition for improving bone joints and promoting bone health as well as a preparation method and application thereof, and relates to the technical field of compositions. The composition is prepared from N-acetylglucosamine and a turmeric extract. The composition can improve the differentiation activity of cartilage precursor cells, effectively promote synthesis of cartilage matrixes, increase the structural construction ability of cartilage tissues, reverse expression down-regulation of cartilage synthesis markers, down-regulate abnormally high expression of cartilage decomposition markers and maintain metabolic balance of cartilage synthesis and decomposition, and has the effects of improving the cartilage tissue differentiation activity and improving the cartilage tissue differentiation activity. Abnormal high secretion of tumor necrosis factors alpha and interleukin 6 in LPS-induced cartilage cells is reduced, and the effects of resisting inflammation, resisting cartilage degradation and maintaining cartilage metabolism balance are achieved.

Compositions comprising a condensed mesenchymal cell body and a hydrogel are provided. The compositions may further include drugs or growth factors. The condensed mesenchymal cell body may include a connective tissue cell, or even a progenitor cell capable of producing connective tissue extracellular matrices such collagen and glycosaminoglycan. Also provided are methods of treating connective tissue defects, cartilage injury, and cartilage degradation.

The invention discloses an oleanolic acid cubic liquid crystal nanoparticle temperature-sensitive gel preparation and application thereof. The preparation is prepared by dispersing oleanolic acid cubic liquid crystal nanoparticles in a temperature-sensitive gel matrix, the oleanolic acid cubic liquid crystal nanoparticles are prepared from oleanolic acid, phytantriol and a stabilizer, and the temperature-sensitive gel matrix is composed of poloxamer F127 and poloxamer F68. The preparation disclosed by the invention has good temperature-sensitive characteristic, slow release performance and joint lubrication function, and can effectively prolong the residence time of oleanolic acid in a joint cavity and improve the bioavailability of oleanolic acid. Experimental results show that the preparation can effectively relieve pain and depression-like behaviors related to knee osteoarthritis, inhibit cartilage degradation and subchondral osteosclerosis, regulate inflammatory factors and oxidative stress indexes and systematically improve the functions of hippocampus through a brain-bone axis, and has important clinical application value.

The invention relates to a preparation method of an anti-inflammatory-cartilage protection double-effect synergistic osteoarthritis microneedle, which comprises the following steps: mixing lecithin, cholesterol, baicalein, naringenin and chloroform methanol to obtain a lipid film, and drying; adding poly (butylene succinate) into the lipid film, hydrating to obtain a liposome suspension, extruding the liposome suspension through a polycarbonate film to obtain a drug-loaded liposome solution, and storing the drug-loaded liposome solution; preparing a mold; adding hyaluronic acid into the drug-loaded liposome solution, uniformly mixing, and pouring into a mold to form a needle body of the microneedle; polyvinylpyrrolidone and polyvinyl alcohol are added into the mold, and a flexible lining plate is formed at the tail of the needle body; and demolding and storing the microneedle. Baicalein and naringenin are jointly loaded into a Baii + Nr microneedle, OA inflammation and cartilage degradation are inhibited at the same time through a complementary mechanism, and synergistic interaction treatment is achieved. Hyaluronic acid is adopted as a matrix, so that the hydrogel has excellent biocompatibility and degradability, and the local drug concentration can be improved.

The present invention relates to a nanobody that specifically binds to vaspin (visceral adipose tissue-derived serine protease inhibitor) and a pharmaceutical composition comprising the same for the prevention or treatment of osteoarthritis, wherein the invention is based on the finding that vaspin protein expression is elevated in cartilage tissues and chondrocytes under osteoarthritis-inducing conditions, leading to increased cartilage degradation and a high-affinity nanobody specific for vaspin was screened using bio-panning of a VHH phage display library. The screened nanobody was shown to suppress cartilage destruction in osteoarthritis models.

The application relates to the field of biomedical technology, and particularly discloses application of an exosome overexpressing CAP and LGR5 genes in preparation of a drug for treating cartilage inflammation. The exosome overexpressing the CAP and LGR5 genes has both targeting property and cartilage protection function, the exosome can be more phagocytosed by cartilage cells, is targeted to the cartilage cells, can improve the levels of a cartilage generation gene Col2a1 and a cartilage development regulating gene Sox9, can reduce the level of a cartilage degradation gene Mmp13, can relieve cartilage abrasion of osteoarthritis mice, and can protect knee joints, so that the exosome can promote cartilage generation, relieve cartilage aging and reduce cartilage degradation under a complex inflammation environment. Further, the application provides a mesenchymal stem cell exosome overexpressing CAP / LGR5, provides a new technical scheme for targeted treatment based on stem cell engineering, and has a wide application prospect.

The application belongs to the field of traditional Chinese medicine, and discloses a traditional Chinese medicine composition for treating arthritis-osteoporosis, wherein raw medicinal materials of the composition include Astragalus membranaceus, Atractylodes macrocephala, Pericarpium Citri Reticulatae Viride, Cimicifuga foetida, Bupleurum chinense, qi-replenishing medicinal materials, Radix Glycyrrhizae Praeparata, Angelica sinensis, blood-activating medicinal materials and Radix Salicae soaked in Radix Glycyrrhizae. The application adds Chuanxiong Rhizoma and Radix Salicae to the Buzhong Yiqi Decoction. The cold-dredging property of Radix Salicae effectively relieves the KOA local "deficiency in origin and heat in superficiality" pathogenesis, and embodies the whole regulation wisdom of "removing blood stasis to generate new blood". By interfering with the common pathological link (qi deficiency and blood stasis), the application realizes the synchronous treatment of arthritis and osteoporosis. Different from the single anti-inflammatory effect of traditional medicine, the application has the dual effects of "promoting bone formation" and "inhibiting cartilage degradation", and can fundamentally stabilize the joint structure and delay the "straight leg bending". Mechanism research shows that the application plays the pharmacological effect by regulating the SRC / STAT3 / AKT1-PI3K-Akt / TNF signal pathway, and the effect is clear.

It is an object of the present invention to provide a highly safe protease (collagenase) that is useful for food or medical applications, such as collagen tripeptide production or cartilage degradation, the intended use thereof, and the like. According to the present invention, provided is an enzyme agent for collagen tripeptide production, comprising, as an active ingredient, a collagenase consisting of the amino acid sequence as set forth in SEQ ID NO: 1 or an amino acid sequence equivalent thereto.

Disclosed herein are methods of treating or preventing rheumatoid arthritis by administering a syndecan-1 inhibitor or a synthenin-1 inhibitor capable of preventing syndecan-1 from binding to the PDZ-2 domain of syntenin-1. Also disclosed herein are methods of reducing or ameliorating one or more symptoms of rheumatoid arthritis, reducing syntenin-1 or syndecan-1 in synovial fluid or blood, reducing synovial inflammation, reducing cartilage degradation, reducing one or more inflammatory interferon transcription factors, reducing one or more monokines, reducing expression of one or more glycolytic factors, or increasing expression of one or more oxidative intermediates or enzymes in a subject.